1. Williams R. Global challenges in liver disease. Hepatology 2006;44:521-526.
2. Cárdenas A, Ginès P. Management of patients with cirrhosis awaiting liver transplantation. Gut 2011;60:412-421.
3. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002;35(5 Suppl 2):S79-S85.
4. Tandon P, Garcia-Tsao G. Portal hypertension and hepatocellular carcinoma: prognosis and beyond. Clin Gastroenterol Hepatol 2006;4:1318-1319.
6. Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010;30:1403-1413.
8. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1616.
9. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases. Radiology 2003;227:89-94.
11. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:166-173.
14. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012;18:1209-1216.
16. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 2013;47:861-870.
17. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant 2013;13:1549-1556.
19. Sekimoto T, Maruyama H, Kondo T, Shimada T, Takahashi M, Yokosuka O, et al. Virtual laparoscopy: initial experience with three-dimensional ultrasonography to characterize hepatic surface features. Eur J Radiol 2013;82:929-934.
20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: vascular diseases of the liver. J Hepatol 2016;64:179-202.
21. Kim MY, Baik SK, Park DH, Lim DW, Kim JW, Kim HS, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int 2007;27:1103-1110.
23. Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, et al. Impact of portal hemodynamics on doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Scan J Gastroenterol 2016;51:236-244.
25. Garcia-Pagán JC, Barrufet M, Cardenas A, Escorsell A. Management of gastric varices. Clin Gastroenterol Hepatol 2014;12:919-928 e1; quiz e51-e52.
26. Maruyama H, Kamezaki H, Kondo T, Sekimoto T, Shimada T, Takahashi M, et al. The application of transabdominal 3D ultrasound for the diagnosis of gastric varices: a preliminary study. Eur J Radiol 2013;82:e400-e404.
27. Maruyama H, Kamezaki H, Takahashi M, Okugawa H, Yokosuka O. The potential of transabdominal 3D color doppler ultrasonography for diagnosis of gastric varices. J Clin Gastroenterol 2014;48:629-634.
28. Maruyama H, Ishihara T, Ishii H, Tsuyuguchi T, Yoshikawa M, Matsutani S, et al. Blood flow parameters in the short gastric vein and splenic vein on Doppler ultrasound reflect gastric variceal bleeding. Eur J Radiol 2010;75:e41-e45.
29. Maruyama H, Okugawa H, Yoshizumi H, Kobayashi S, Yokosuka O. Hemodynamic features of gastrorenal shunt: a Doppler study in cirrhotic patients with gastric fundal varices. Acad Radiol 2008;15:1148-1154.
30. Maruyama H, Okugawa H, Kobayashi S, Yoshizumi H, Yokosuka O. Pre-treatment hemodynamic features involved with long-term survival of cirrhotic patients after embolization of gastric fundal varices. Eur J Radiol 2010;75:e32-e37.
32. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187-210.
33. Cobbold JF, Patel D, Fitzpatrick JA, Patel N, Crossey MM, Abdalla MS, et al. Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C. Hepatol Res 2012;42:515-522.
35. Li N, Ding H, Fan P, Lin X, Xu C, Wang W, et al. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasoud Med Biol 2010;36:1066-1075.
36. Cobbold JF, Crossey MM, Colman P, Goldin RD, Murphy PS, Patel N, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat 2010;17:537-545.
39. Orlacchio A, Bolacchi F, Petrella MC, Pastorelli D, Bazzocchi G, Angelico M, et al. Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results. Ultrasound Med Biol 2011;37:1-6.
40. Ishibashi H, Maruyama H, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Assessment of hepatic fibrosis by analysis of the dynamic behavior of microbubbles during contrast ultrasonography. Liver Int 2010;30:1355-1363.
47. Kim MY, Suk KT, Baik SK, Kim HA, Kim YJ, Cha SH, et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012;56:1053-1062.
53. Guo Y, Hu Y, Qiao M, Wang Y, Yu J, Li J, et al. Radiomics analysis on ultrasound for prediction of biologic behavior in breast invasive ductal carcinoma. Clin Breast Cancer 2018;18:e335-e344.